Provided by Tiger Trade Technology Pte. Ltd.

NovoCure

14.87
+0.46003.19%
Volume:1.35M
Turnover:19.98M
Market Cap:1.67B
PE:-9.25
High:14.95
Open:14.27
Low:14.13
Close:14.41
52wk High:28.56
52wk Low:10.70
Shares:111.98M
Float Shares:94.15M
Volume Ratio:0.98
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6074
EPS(LYR):-1.5638
ROE:-50.60%
ROA:-8.30%
PB:4.88
PE(LYR):-9.51

Loading ...

Company Profile

Company Name:
NovoCure
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
1488
Office Location:
Neuhofstrasse 21,Baar,Zug,Switzerland
Zip Code:
6340
Phone:
- -
Fax:
- -
Introduction:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Directors

Name
Position
William F. Doyle
Executive Chairman and Director
Allyson Ocean
Independent Director
David Hung
Independent Director
Jeryl Hilleman
Independent Director
Kinyip Gabriel Leung
Independent Director
Kristin Stafford
Independent Director
Martin J. Madden
Independent Director
Timothy Scannell
Independent Director
William A. Vernon
Independent Director

Shareholders

Name
Position
Francis Leonard
President and Chief Executive Officer
Mukund Paravasthu
Chief Operating Officer
Christoph Brackmann
Chief Financial Officer
Barak Ben Arye
General Counsel
Michael Puri
Chief Human Resources Officer
Nicolas Leupin
Chief Medical Officer
Uri Weinberg
Chief Innovation Officer